Biointron’s Q3 2025 antibody industry report aims to explore the events and trends of the biopharmaceutical industry in July, August, and September. This quarter, 2 novel monoclonal antibody drugs have been approved by at least one regulatory agency around the world: both from China.
Over the past few months, the biotech landscape saw venture funding of antibody companies with significant seed-to-Series D rounds across a wide range of disease areas. A key trend emerging is the diversification of antibody modalities, spanning bispecifics, antibody-drug conjugates (ADCs), radioiso
As viral threats continue to emerge and evolve, a new generation of antibody formats, derived from birds, camelids, and sharks, is gaining traction as a promising alternative for rapid, scalable, and resilient immunotherapies.A recent review by Basabrain & Alandijany (2025) describes how avian i
Time: September 22 - 25, 2025
Location: Boston, MA
Booth: #410
Time: September 30 - October 2, 2025
Location: Basel, Switzerland
Booth: #713
Time: October 8 - 10, 2025
Location: Yokohama, Japan
Booth: #D63
Developability is an increasingly critical concept in antibody discovery and development. Previously associated with late-stage outcomes such as stability and formulation, developability assessment is now integrated earlier in the discovery process to enable multidimensional profiling of lead candidates.
WhenThursday, October 16, 2025 · 11:00 a.m.Eastern Time (US & Canada) (GMT -4:00)Register here >>AboutSuccessful antibody discovery requires more than just access to powerful platforms - it demands the experience to apply them efficiently and strategically.In this webinar, we
Biointron’s Lunch & Learn with KACTUS was held at CIC Cambridge, MA on September 12. The session featured three key speakers: Sagar Kathuria, PhD (Senior Principal Scientist at Sanofi), Alexander Hostetler, PhD (Application Scientist at KACTUS Biosystems), and Gang Liu, PhD (Director of Discovery Services at Biointron). We thoroughly enjoyed hosting the event and the audience’s strong engagement!
When you’re a small biotech with big ambitions, every week counts. For Macomics Limited, that meant finding a way to get high-quality antibodies quick···
The demand for fully human therapeutic antibodies continues to grow, driving the need for more efficient discovery platforms.
Case 1: Tag-Free Vaccine Protein. During the generation of stable cell lines, cells are selected and screened to identify clones that stably express t···
Apply for Biointron's Quarterly Travel Grant. Receive $800 to support early-career antibody researchers in attending scientific conferences, symposia, and workshops.
Submit a quick Biointron testimonial and we’ll send you a $25 Amazon gift card. Simple, fast, and appreciated!
Join Biointron’s Google Review & Reward Program! Share your experience on Biointron google profile and earn a $25 gift card as reward!
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This October, we'll highlight advances in antibody design with AI, crossing the BBB, and universal antibodies.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This September we'll highlight recent approvals in biosimilar drugs, conjugate linker designs, and discovery platform advances.
Spotlight on Antibodies is a podcast from Biointron, where we bring you the latest antibody industry trends. This August, we highlight drug advances in autoimmune and infectious diseases, as well as next-generation immune cell engagers.
PEGS Europe2025 conference was held inLisbon, Portugal, fromNovember11to November13, 2025.The Proteinand Antibody Engineering Summithad focusedsessions onbispecifics,multispecifics, machine learning, and novel target engagement
Antibody discovery has traditionally relied on selecting clones based on target binding. However, for therapeutic applications, the desired antibodies must also drive a functional response, such as receptor activation, T cell stimulation, or signaling modulation. Identifying these antibodies early in discovery can significantly reduce downstream risk and accelerate lead optimization.
The Society for Immunotherapy of Cancer (SITC) 2025 conference was held in National Harbor, Maryland, from November 5 to November 9, 2025. Forty years ago, breakthroughs in recombinant DNA, monoclonal antibody technology, and tumor immunology laid the groundwork for cancer research. At SITC, experts and emerging investigators across biotech, academia, government, and pharma come to advance immuno-oncology and improve patient outcomes.
You can also contact us on the Scientist and Science Exchange marketplaces.
